The Schwab U.S. Dividend Equity ETF (SCHD) enters what analysts call a “redemption year,” as many long-term investors reassess holdings and seek defensive positioning against high S&P 500 valuations. With the 2-year Treasury yield near 3.5%, SCHD’s focus on dividend discipline could attract capital shifting from overvalued growth names into stable income streams. Industry research projects that a growth-to-value rotation may gain momentum in 2026, and SCHD’s track record of rising distributions—an average annual dividend growth rate of roughly 7% over the past five years—positions it to benefit from renewed interest in cash returns.

SCHD’s portfolio tilts heavily into energy and healthcare, sectors that currently represent about 20% and over 16% of assets, respectively. Major energy holdings such as Chevron and ConocoPhillips benefit from robust free cash flow and trade at discounts to their five-year average enterprise multiples, despite recent weakness in oil benchmarks. In healthcare, companies like Bristol-Myers Squibb, Merck and AbbVie are restoring momentum through resilient capital allocation and margin expansion driven by strong patent-protected drug franchises. Relative to broad market averages, SCHD’s sector blend trades at approximately a 10% valuation discount on price-to-cash-flow metrics.

SCHD’s selection criteria emphasize sustainable payout ratios below 60%, consistent free cash flow generation and a minimum five-year dividend growth track record. This translates into a portfolio yield near 3.8%, backed by blue-chip companies with average cash-flow coverage ratios exceeding 1.5x. For income-seeking investors, SCHD offers a cost-effective way to capture high-quality dividends, with an expense ratio of just 0.06%. Over the past decade, the ETF has delivered an annualized total return of roughly 11%, underscoring its role as a core income sleeve in a diversified portfolio heading into 2026.